.png)
The Immune Oncology Research Institute, in collaboration with Agenus Biotechnology Company, has launched a new trial in June 2024, which will assess the safety and efficacy of the anti-CTLA-4 agent botensilimab in combination with anti-PD-1 antibody balstilimab in the frontline treatment of metastatic non-small cell lung cancer (NSCLC).
The study enrolls participants with a histologically confirmed diagnosis of metastatic NSCLC and without targetable EGFR mutation or ALK rearrangement, while excluding those with untreated brain metastases or oligometastatic disease lacking targetable lesions. It is set to recruite 45 patients. 3 patients have already been recruited.
The total estimated maximum time of study participation for each patient is approximately 49 months across 3 periods.
This study received the approval of the Center of Drug and Medical Technology in just 30 working days, followed by the approval of the Ethics Committee of the Ministry of Health within 9 working days.
The Principal Investigator of the trial is Dr. Samvel Bardakhchyan, the study team includes Prof. Gevorg Tamamyan Dr. Davit Zohrabyan, Dr. Liana Safaryan, and Dr. Amalya Sargsyan.
About IMMONC
Immune Oncology Research Institute (IMMONC) is dedicated to advancing research aimed at preventing, treating, and ultimately curing cancer while making these innovations accessible to those who need them. If you're interested in joining our team, please feel free to contact us at [email protected] or at +374-41 310-048.